TrialBritish journal of cancer2025

Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial.

Desmond Yip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.